GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Infinity Pharmaceuticals, Inc. (INFI) [hlAlert]

Rating:
Buy INFI
down 27.73 %

Infinity Pharmaceuticals, Inc. (INFI) rated Buy with price target $20 by Deutsche Bank

Posted on: Thursday,  May 7, 2015  1:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) on 05/07/2015, when the stock price was $12.62. Since
then, Infinity Pharmaceuticals, Inc. has lost 27.73% as of 01/25/2016's recent price of $9.12.
If you would have followed this Deutsche Bank's recommendation on INFI, you would have lost 27.73% of your investment in 263 days.

Infinity Pharmaceuticals, Inc. (IPI) has developed a pipeline of product candidates for multiple cancer indications. The Company?s lead product candidate, retaspimycin hydrochloride (IPI-504) is an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a central component of the cellular chaperone system, which supports and stabilizes cancer-causing proteins, such as c-Kit, EGFR, and HER2, enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death. In October 2008, the commenced an international Phase III registration study of IPI-504 in patients with refractory gastrointestinal stromal tumors (GIST), based on the activity and safety data from a Phase I trial reported during the year ended December 31, 2008.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/7/2015 1:25 PM Buy
None
12.62 20.00
as of 8/27/2015
1 Week up  7.67 %
1 Month down  -22.05 %
3 Months down  -25.55 %
1 YTD down  -27.73 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy